Exploring the relationship between motor impairment, vascular burden and cognition in Parkinson’s disease
To determine frequency and type of cognitive disorders in cross-sectional analysis of a Parkinson’s disease (PD) cohort, and explore its relations to motor symptoms, modifiable vascular risk factors and white matter lesions (WML) volume.
In a group of 133 PD patients, mild cognitive impairment (PD-MCI) and dementia (PDD) were diagnosed according to Movement Disorders Society Task Force criteria (level 2 for PD-MCI). Detailed motor measurements were applied, including rigidity, axial, bradykinesia, tremor and postural instability gait disorders (PIGD) scores. Vascular risk was estimated by the Framingham General Cardiovascular Disease risk scoring algorithm and WML volume was measured for whole brain and frontal lobe.
Sixty-one (46.9%) patients fulfilled criteria for PD-MCI, and 23 (17.7%) for PDD. Non-amnestic multiple domain MCI was most frequent (52% of PD-MCI patients). Motor scores were significantly higher in cognitively impaired patients, but only axial score discriminated between MCI and dementia. High vascular risk was related to impaired cognition, bradykinesia, axial, PIGD and freezing of gait (FOG) score, while whole brain WML volume was associated with PDD, FOG and attention deficits. Furthermore, high vascular risk was identified as a potential predictor of both MCI and dementia in PD. Additionally, age and bradykinesia score were independently associated with PD-MCI and age, axial score and whole brain WML volume with PDD.
Cognitive disorders in PD are associated with more severe, predominantly axial motor deficits and increased, but partly modifiable vascular burden, thus opening a possibility for development of preventive strategies in PD.
KeywordsParkinson’s disease Cognition Gait Vascular risk
Compliance with ethical standards
Conflicts of interest
T. Stojkovic has received speaker honoraria from Actavis and research grant from the Ministry of Education and Science, Republic of Serbia, as well as Alzheimer’s Association International Research Grant. E. Stefanova has received speaker honoraria from Novartis, Glaxo Smith Kline and Boehringer Ingelheim, research grant from the Ministry of Education and Science, Republic of Serbia, as well as Alzheimer’s Association International Research Grant. I. Soldatovic. Declarations of interest: none. V. Markovic has received research grants from the Ministry of Education and Science, Republic of Serbia. I. Stankovic has received research grants from the Ministry of Education and Science, Republic of Serbia. I Petrovic has received speaker honoraria from Boehringer Ingelheim, GSK, El pharma, Roche, Actavis and research grants from the Ministry of Education and Science, Republic of Serbia. F. Agosta is Section Editor of NeuroImage: Clinical; has received speaker honoraria from Biogen Idec, Novartis, and ExceMED—Excellence in Medical Education; and receives or has received research supports from the Italian Ministry of Health, AriSLA (Fondazione Italiana di Ricerca per la SLA), and the European Research Council. S. Galantucci. Declarations of interest: none. M. Filippi is Editor-in-Chief of the Journal of Neurology; serves on a scientific advisory board for Teva Pharmaceutical Industries; has received compensation for consulting services and/or speaking activities from Biogen Idec, ExceMED, Novartis, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer’s Drug Discovery Foundation (ADDF), the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione Italiana di Ricerca per la SLA). V. Kostic serves on the editorial board of the Journal of Neurology; has received research grants from Ministry of Education and Science, Republic of Serbia, and the Serbian Academy of Science and Arts; and receives research support from Valeant, Stada, Novartis, and Boehringer Ingelheim, and speaker honoraria from Novartis and Boehringer Ingelheim.
The local Ethical Committee (School of Medicine, University of Belgrade, Serbia) approved the study protocol and all participants signed written informed consent.
- 6.Kelly VE, Johnson CO, McGough EL, Shumway-Cook A, Horak FB, Chung KA, Espay AJ, Revilla FJ, Devoto J, Wood-Siverio C, Factor SA, Cholerton B, Edwards KL, Peterson AL, Quinn JF, Montine TJ, Zabetian CP, Leverenz JB (2015) Association of cognitive domains with postural instability/gait disturbance in Parkinson’s disease. Parkinsonism Relat Disord 21:692–697CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Malek N, Lawton MA, Swallow DM, Grosset KA, Marrinan SL, Bajaj N, Barker RA, Burn DJ, Hardy J, Morris HR, Williams NM, Wood N, Ben-Shlomo Y, Grosset DG, PRoBaND Clinical Consortium (2016) Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson’s disease. Mov Disord 31(10):1518–1526CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Marin RS (1996) Apathy, concept, syndrome, mechanisms and treatment. Neural Clin Neuropsychiatry 1:303–314Google Scholar
- 24.Lezak M (1983) Neuropsychological assessment, 2nd edn. Oxford University Press, New YorkGoogle Scholar
- 26.Stefanova E, Žiropadja L, Stojković T, Stanković I, Tomić A, Ječmenica-Lukić M, Petrović I, Kostić V (2015) Mild cognitive impairment in early Parkinson’s disease using the Movement Disorder Society Task Force criteria: cross-sectional study in Hoehn and Yahr stage 1. Dement Geriatr Cogn Disord 40:199–209CrossRefPubMedGoogle Scholar
- 27.Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease. Mov Disord Soc Task Force Guidel Mov Disord 27:349–356CrossRefGoogle Scholar
- 28.Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324CrossRefPubMedGoogle Scholar
- 29.Biundo R, Weis L, Antonini A (2016) Cognitive decline in Parkinson’s disease the complex picture, npj. Parkinson’s Dis 2:1–7Google Scholar